It is currently accepted that the neural transduction pathways of gastrointestinal (GI) visceral pain include the peripheral and central pathways. Existing research on the neurological mechanism of electroacupuncture (EA) in the treatment of GI visceral pain has primarily been concerned with the regulation of relevant transduction pathways. The generation of pain involves a series of processes, including energy transduction of stimulatory signals in the sensory nerve endings (signal transduction), subsequent conduction in primary afferent nerve fibers of dorsal root ganglia, and transmission to spinal dorsal horn neurons, the ascending transmission of sensory signals in the central nervous system, and the processing of sensory signals in the cerebral cortex. Numerous peripheral neurotransmitters, neuropeptides, and cytokines participate in the analgesic process of EA in visceral pain. Although EA has excellent efficacy in the treatment of GI visceral pain, the pathogenesis of the disease and the analgesic mechanism of the treatment have not been elucidated. In recent years, research has examined the pathogenesis of GI visceral pain and its influencing factors and has explored the neural transduction pathways of this disease.
Objective. To explore whether the effect of electroacupuncture (EA) on visceral hypersensitivity (VH) in rats with irritable bowel syndrome (IBS) is related to the changes of astrocyte activation in the medial thalamus (MT) and anterior cingulate cortex (ACC). Method. Male Sprague‐Dawley rats were randomly divided into the normal control (NC) group, model control (MC) group, electroacupuncture (EA) group, and fluorocitrate (FCA) group. A model of visceral hypersensitivity was established by neonatal colorectal irritation. In the EA group, needles were inserted into the skin at the Tianshu (ST25) and Shangjuxu (ST37) acupoints, once a day for 7 days. The FCA group received intrathecal injection of FCA on the 1st, 4th, and 7th days. Visceral hypersensitivity was evaluated by the abdominal withdrawal reflex (AWR), and glial fibrillary acidic protein (GFAP) mRNA and protein levels in the MT and ACC were detected by real‐time PCR, immunohistochemistry, and western blots. Results. The AWR score in the MC group was significantly higher than in the NC group, and EA and FCA reduced the AWR score of VH rats. GFAP mRNA and protein levels in the MT and ACC of rats in the MC group were significantly increased compared with the NC group. After either electroacupuncture or fluorocitrate, GFAP mRNA and protein levels in the MT and ACC were both clearly reduced. Conclusion. Electroacupuncture alleviates IBS visceral hypersensitivity by inhibiting the activation of astrocytes in the MT and ACC.
Objectives: The aim of this study was to observe the clinical effectiveness of simultaneous electroacupuncture stimulation on the tibial nerve (TN) and ilioinguinal-iliohypogastric nerve (IIN/IHN) in the treatment of refractory overactive bladder (OAB) in women. Materials and methods: A prospective study was conducted involving 94 female patients with a diagnosis of OAB in the Urology Department of our hospital from September 2022 to October 2023. The patients were randomly divided into a TN-IIN/IHN group and a control group, each comprising 47 cases. All patients in both groups had received anticholinergic muscarinic receptor antagonists (tolterodine/solifenacin), β3 receptor agonists, flupentixol/melitracen, and other basic treatment regimens with poor results. The TN-IIN/IHN group received simultaneous electroacupuncture on the TN and IIN/IHN, whereas the control group received pelvic floor muscle biofeedback electrical stimulation. Both groups underwent treatment 3 times a week for a total of 4 weeks. Bladder symptoms (24-hour voiding diary), OAB Symptom Score, OAB-Quality of Life Questionnaire, and anxiety and depression scores were compared and analyzed before treatment, after treatment, and at a 3-month follow-up. Clinical efficacy was also assessed. Results: Both groups showed significant improvement in voiding frequency, nocturia, urgency, OAB Symptom Score, and average voiding volume after treatment and at follow-up (p < 0.01). The TN-IIN/IHN group showed significantly superior results compared with the control group (p < 0.01). Quality of life scores and anxiety and depression scores significantly decreased (p < 0.01), with the TN-IIN/IHN group scores significantly lower than those of the control group (p < 0.01). The treatment success rate in the TN-IIN/IHN group was 84.78%, whereas that in the control group was 28.89%, showing a statistically significant difference (p < 0.01). No significant adverse reactions occurred in either group during the treatment period. Conclusions: Simultaneous electroacupuncture on the TN and IIN/IHN is effective in treating refractory OAB in women and has good long-term efficacy. This therapy is safe, convenient, and free of significant adverse reactions, providing a new approach for the clinical treatment of refractory OAB in these patients. It significantly improves bladder symptoms and alleviates anxiety and depression, thereby markedly enhancing the patients' quality of life.
1 January 2024 in JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
Background: Despite the coexpression of Lysophosphatidic Acid-1 (LPA1) and purinergic receptor P2X, ligand-gated ion channel 3 (P2X3) receptors in vesicle-associated primary sensory neurons, their potential interaction contributing to bladder pain pathophysiology remains obscure. In this study, we aimed to investigate whether the interaction between LPA1 and P2X3 receptors in dorsal root ganglion (DRG) neurons drives the development of cyclophosphamide (CYP) -induced bladder pain syndrome. Methods: We induced bladder pain syndrome in male C57BL/6J mice via intraperitoneal administration of CYP (300 mg/kg). The experimental mice are grouped into saline (i.t.), CYP (i.p.), LPA (i.t.), Ki16198 (i.t.), A317491 (i.t.). A combination of behavioral, neuropharmacological, molecular biological, neuroretrograde tracing, and electrophysiological techniques was employed to investigate the mechanisms of LPA1 and the P2X3 receptor in bladder pain syndrome. Results: Administration of CYP resulted in bladder pain-like nociceptive behavior and a significant surge in urinary bladder LPA content and triggers the release of inflammatory factors Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-κB) and Interleukin-1 beta (IL-1β), resulting in pain-like nociceptive behavior. Nociceptive behavior was emulated through intrathecal injection of LPA (2.5 μg, 5 μL), which was significantly mitigated by the LPA1 receptor antagonist, Ki16198. α,β-meATP (100 μM) induced a significant increase in inward currents and action potential frequency in mouse DRG neurons, which was effectively counteracted by Ki16198. Direct application of LPA under physiological conditions also amplified the function of P2X3 receptors. While Ki16198 did not influence the upregulation of phosphorylated Extracellular Signal-Regulated Kinase (p-ERK) protein, it notably inhibited p38 protein. The selective p-38 antagonist SB202190 inhibited the upregulation of P2X3 recepor (P2X3R) as well as the levels of NF-κB and IL-1β, both of which were suppressed by the application of Ki16198 (i.t.). Conclusions: In summary, our study suggests that targeting the p38 mitogen-activated protein kinase (MAPK) signaling pathway may offer therapeutic potential for alleviating bladder pain in mice by mitigating the sensitization of LPA-LPA1 receptor signaling to the nociceptive receptor P2X3R in DRG neurons.